- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Amphivena Therapeutics Inc.
Headquarters: South San Francisco, CA, United States of America
Website: http://www.amphivena.com
Year Founded: 2013
Status: Private
BioCentury | Apr 22, 2022
Management Tracks
Promotions at Twist, as COO steps down
Plus CFO retires at Travere and updates from
BioCentury | Dec 4, 2019
Company News
Management tracks: Mittal to succeed Biocon’s Chandavarkar; plus Intercept, Nektar, Agios, Accelerate, ABPI and more
BioCentury | Sep 24, 2019
Financial News
Amphivena to expand clinical program, T cell engager pipeline with $62M series C
BioCentury | Mar 9, 2019
Company News
Management tracks: Lundbeck hires first CBO; ICT opens U.S. office
BioCentury | Dec 8, 2018
Product Development
Intermittent move beyond Blincyto
How new bispecifics at ASH are improving on dosing, toxicity short comings of Blincyto
BioCentury | Dec 1, 2018
Product Development
Cell therapy momentum at ASH
A survey of clinical abstracts at ASH 2018 highlights momentum in CAR Ts
BioCentury | Jun 25, 2015
Product R&D
Cellectis' UCART-ography
How CAR T cells made from healthy donors could treat leukemia
BioCentury | Jun 11, 2015
Product R&D
All four one
How a four-domain biologic triggers T cells to kill myeloid leukemias
Items per page:
1 - 10 of 14